Neurocrine Biosciences Inc. blamed a too-low dose for the failure of Ingrezza (valbenazine) in a Phase II pediatric Tourette's syndrome clinical trial and while many analysts conceded that a planned Phase IIb study with a higher dose may produce a positive result, they expect approval to be delayed by a few years.
Neurocrine Blames Sub-Par Dosing For Ingrezza Study Failure
Neurocrine's stock fell 9% on May 24 after the company said a closely-watched Phase II study for Ingrezza in pediatric Tourette's syndrome failed, but blamed a sub-therapeutic dose for the disappointing results. Most analysts gave the prospects for a higher dose study the benefit of the doubt.
